先声药业(02096.HK) 公布，旗下“先必新®舌下片”于昨日(1日)获中国国家药监局批准在中国上市，用于改善急性缺血性脑卒中所致的神经症状、日常生活活动能力和功能障碍。
据介绍，上述药物片是一种脑细胞保护剂，由依达拉奉和右莰醇两种活性成分组成，具有抗氧化、抗炎和协同增效作用，能够显著减少AIS导致的脑细胞损伤。另外，“先必新®舌下片”有望与先声药业已上市的“先必新®注射剂”组成序贯疗法，利于患者在院内院外获得完整疗程。(js/w)
(港股报价延迟最少十五分钟。沽空资料截至 2024-11-29 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.